コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 n carcinoma and 24 patients with a secondary ovarian neoplasm.
2 fining a genotypic-phenotypic correlation in ovarian neoplasms.
3 ared between primary and secondary malignant ovarian neoplasms.
4 in BRCA1 confer susceptibility to breast and ovarian neoplasms.
5 interstitial loss defined in both breast and ovarian neoplasms.
6 th broad applicability to pathologies beyond ovarian neoplasms.
7 er Intergroup International Collaboration on Ovarian Neoplasms 7 (ICON7) trial, bevacizumab improved
8 ucing salpingo-oophorectomy, one early-stage ovarian neoplasm and one early-stage fallopian tube neop
9 unction, confer susceptibility to breast and ovarian neoplasms and are thought to be responsible for
11 tomies, defined as oophorectomy for a benign ovarian neoplasm based on final pathology or mass resolu
13 hese trials [the International Collaborative Ovarian Neoplasm Group trial (ICON7), the Gynecologic On
14 differentiate between primary and metastatic ovarian neoplasms in the diagnosis and staging of ovaria
15 ain's underlying propensity for DMBA-induced ovarian neoplasms, our studies underscore the specific i
16 thelium and of gonadotropin-binding sites in ovarian neoplasms provide additional evidence supporting
17 imilarly to progression of disease in women, ovarian neoplasms spread i.p., forming ascites, and meta
18 lts of the large International Collaborative Ovarian Neoplasm Study (ICON2) showed no survival differ
19 represent a distinct category of epithelial ovarian neoplasms that have a clinically more favorable
20 mors, all PGRB-overexpressing mice developed ovarian neoplasms that were derived from ovarian luteal
21 e genetic alterations in 108 sporadic serous ovarian neoplasms to elucidate ovarian serous carcinogen
22 ient population (International Collaborative Ovarian Neoplasm Trial 1/European Organization for Resea
23 Treatment of Cancer Adjuvant Chemotherapy in Ovarian Neoplasm Trial) are being discussed with patient